Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.

Usmani, Saad Z; Khan, Imran; Chiu, Christopher; Foureau, David; Druhan, Lawrence J; Rigby, Katherine; Casneuf, Tineke; Sasser, A Kate

Usmani, Saad Z; Khan, Imran; Chiu, Christopher; Foureau, David; Druhan, Lawrence J; Rigby, Katherine; Casneuf, Tineke; Sasser, A Kate.

Afiliação

Usmani SZ; Levine Cancer Institute/Carolinas Health Care System, 1021 Morehead Medical Drive, Charlotte, NC 28204 USA.
Khan I; 2Janssen Research & Development, LLC, Raritan, NJ USA.
Chiu C; 3Janssen Research & Development, LLC, Spring House, PA USA.
Foureau D; Levine Cancer Institute/Carolinas Health Care System, 1021 Morehead Medical Drive, Charlotte, NC 28204 USA.
Druhan LJ; Levine Cancer Institute/Carolinas Health Care System, 1021 Morehead Medical Drive, Charlotte, NC 28204 USA.
Rigby K; Levine Cancer Institute/Carolinas Health Care System, 1021 Morehead Medical Drive, Charlotte, NC 28204 USA.
Casneuf T; 4Janssen Research & Development, Beerse, Belgium.
Sasser AK; 3Janssen Research & Development, LLC, Spring House, PA USA.

Exp Hematol Oncol ; 7: 3, 2018.

Article em En | MEDLINE | ID: mdl-29445583

Palavras-chave

Daratumumab; Immune response; Minimal residual disease; Multiple myeloma; Stringent complete response; Sustained response; T-cell expansion; Triple refractory

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Exp Hematol Oncol Ano de publicação: 2018 Tipo de documento: Article País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google